Tired of diets that don't work?
​
We understand the struggles of weight loss and offer solutions that last.
Our comprehensive program supports you in every step of the way:
COMPREHENSIVE EVALUATION for causes of weight gain.
​
BEHAVIOR: Learn behavioral intervention tools to develop healthy lifestyle habits and enhance your weight loss efforts.
EATING: Examine how different types of foods and nutrients can assist in weight loss while also promoting good health.
ACTIVITY: ​Discuss about the role of different types of exercise to help with weight loss and weight maintenance.
MEDICATIONS: We prescribe all FDA-approved medications for weight loss and cardiovascular risk reduction.
FDA-Approved Medications For Weight Loss
Hunger
Fullness
Food Desire
Insulin Resistance
Semaglutide
(GLP-1 Receptor Agonist)
Wegovy, Ozempic, Rybelsus
Phentermine
(Adrenergic Stimulant, FDA approved for short term use)
Adipex, Lomaira
Phentermine/ Topiramate
(Stimulant/Neurostabilizer of GABA Pathway)
Qsymia
Naltrexone/ Bupropion
(Opioid Receptor Antagonist/ Dopamine Pathway)
Contrave
Orlistat
(Pancreatic Lipase inhibitor)
Xenical
DISCLAIMER:
-
Weight loss varies widely among patients when using medications. Not everybody loses the same amount of weight with one type of medication. Sometimes one medication must be complemented with another medication.
​​
-
THE ABOVE MEDICATIONS are FDA-approved for BMI >30 (kg/m2) or for BMI >27 (kg/m2) plus co-morbidity and are to be used only in conjunction with lifestyle modifications.
-
THE ABOVE LIST DOES NOT INCLUDE:
Metformin can help with weight loss but was not approved as a weight-loss drug. A 2020 analysis of studies showed modest (<5%) weight reduction with metformin when used as an adjunct to lifestyle; however, some people may lose more weight than others.
SGLT2 inhibitors (e.g. Dapagliflozin (Farxiga) or Empagliflozin (Jardiance) can aid weight loss but not significantly.
Setmelanotide (Imcivree) prescribed in select patients for genetic conditions associated with obesity.
​
Liraglutide (Saxenda) the first GLP-1 agonist approved for treatment of obesity.
​​
​​
​